Shopping Cart
- Remove All
- Your shopping cart is currently empty
LFHP-1c is a novel PGAM5 inhibitor that shows neuroprotective activity in an ischemic stroke model, preventing BBB destruction after transient middle cerebral artery occlusion (tMCAO) in rats.LFHP-1c can be used to study cerebral ischemic stroke.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $198 | In Stock |
Description | LFHP-1c is a novel PGAM5 inhibitor that shows neuroprotective activity in an ischemic stroke model, preventing BBB destruction after transient middle cerebral artery occlusion (tMCAO) in rats.LFHP-1c can be used to study cerebral ischemic stroke. |
In vitro | In primary rat brain microvascular endothelial cells (rBMECs), LFHP-1c (2 μmol/L; 1 hour) binds to PGAM5, facilitating the nuclear translocation of NRF2[1]. |
In vivo | In the nonhuman primate Macaca fascicularis model with tMCAO, LFHP-1c (3 mg/kg, 1 mL/kg; intravenous injection; at 4 h, 1, 2, 3, 4, 5, 6, and 7 days after tMCAO onset) reduced infarct volume, brain edema, and neurological deficits in the transient MCAO model in M. fascicularis[1]. |
Molecular Weight | 873.13 |
Formula | C55H64N6O4 |
Cas No. | 2102347-47-5 |
Smiles | O=C(OC(C=1C=CC=CC1C(=O)NCCCCCCCCNC(=O)C=2C=CC=CC2C=3C=CC(=CC3)CN4C5=CC(=CC(=C5N=C4CCC)C)C6=NC=7C=CC=CC7N6C)CCCC)C |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (91.62 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.